Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and ...
Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 February 11, 2026 6:30 ...
Human challenge trials offer a complementary approach. By safely and deliberately exposing healthy adult volunteers to a well characterised virus under controlled conditions, researchers can generate ...
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study ...
Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...
The shelter, just south of Grant Line Road, is expected to open in two years, according to Bontrager; the lease on the city’s ...
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript February 9, 2026 Anavex Life Sciences Corp. beats ...
A man convicted of killing a traveling salesman during a 1989 robbery is set to become the first person executed in Florida this year.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses ...
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON ...
Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results